Isaac Francis

Strategy paused reported bitcoin buying activity after executive chairman Michael Saylor said the company “bought bonds, not bitcoin” during the latest week.

Midas Minerals (ASX:MM1) has executed a binding heads of agreement to sell its Newington Project.

Russia will begin requiring crypto miners and mining infrastructure operators to report network address data from May 30 as part of tighter oversight of the country’s digital asset sector.

The United States and Iran are signalling progress towards resolving their conflict, though details of a framework agreement remain under negotiation.

Solana remains in a cautious consolidation phase as traders wait for a clearer signal on the token’s next major direction.

Ethereum remains under market pressure in 2026, but analysts say its long-term investment case continues to draw support from onchain data.

Assembly Biosciences (NASDAQ:ASMB) announced plans to expand the clinical development framework for its experimental compound ABI-6250, pushing the asset beyond its initial virology target into chronic cholestatic liver conditions.

AC Immune (NASDAQ:ACIU) announced positive preliminary Phase 1 clinical data for its experimental brain imaging agent, ACI-19626, expanding its diagnostic reach into amyotrophic lateral sclerosis (ALS).

Ascentage Pharma (NASDAQ:AAPG) announced that abstracts for six of its clinical studies have been published ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, outlining early-phase therapeutic activity across its core pipeline of targeted oncology candidates.

Bitcoin is showing signs of a developing liquidity-driven rally toward $80,000 as more than $4 billion in leveraged short positions remain vulnerable to liquidation above that level.